NoPo Nanotechnologies, a manufacturer of carbon nanotubes, has raised $3 million, or roughly INR 24.9 crore, in pre-series A fundraising led by Inflexor Ventures and Axilor Ventures’ Micelio Fund.
The money raised will be placed to use to expand manufacturing, improve engineering capabilities, and carry out a global go-to-market plan.
Read also – Awfis Secures INR 269 Cr From Anchor Investors Before IPO
With this additional finance, NoPo is improving its products for electronics and semiconductor makers and increasing its production capacity to serve worldwide battery manufacturers.
NoPo is the first company in India and among the few worldwide to have created the technology necessary to manufacture SWCNTs through a patented, exclusive process.
Jatin Desai, managing partner at Inflexor Ventures, said: “Their (Reddy and Bradley) innovations promise to revolutionise many industries including electric vehicles, semiconductors and electronics. We firmly believe that the next-generation material science space holds immense potential for transformative advancements, and we’re eager to be at the forefront of it.”
Gadhadar Reddy, Founder, said: “There are more than 100 applications that are being developed across the world using SWCNTs ranging from desalination to cancer treatment. We are happy to partner with Micelio and Inflexor as they bring with them a wealth of knowledge and expertise in deep-tech and climate space,”
About NoPo Nanotechnologies
Founded in 2011 by Gadhadar Reddy and Kelley Bradley, NoPo Nanotechnologies produces at scale the most cutting-edge carbon nanotubes for the carbon era and its uses.
Want to go deeper into the world of startups and entrepreneurship? Check out these categories on VIESTORIES:
Startup Success Stories: Discover inspiring tales of startups overcoming challenges and achieving success.
Funding Startup News: Stay updated with the latest news and trends in startup funding and investment.
Startup Insights: Dive into in-depth analyses of various industries and market trends to make informed business decisions.
